Florence Healthcare teams with VersaTrial on site enablement
Florence Healthcare has acquired clinical trial site services firm, VersaTrial in a deal designed to further expand its “site enablement” offering.
The agreement gives Florence’s customers access to VersaTrial site engagement platform provides sponsors and clinical research organizations (CROs) with operational insights and access management alerts to ensure measurable site oversight and quality execution.
According to a joint statement, sites, sponsors and CROs will also benefit from real-time site connectivity that will let them “manage clinical studies more efficiently, reduce data duplication, improve site readiness, and enhance communication with sites.”
Florence’s network of 18,000 research sites in more than 55 countries, will integrate VersaTrial’s technologies, which are designed to reduce tech burden, speed up feasibility response times and enhance communication across frequently changing study personnel.
Florence CEO, Ryan Jones, said that the agreement is in keeping with his firm’s focus on making trial sites more efficient.
“VersaTrial and Florence have the opportunity to help every trial site do their best work and get this industry closer to maximizing efficiency and capacity for every research site.”
Mike Wenger, CEO of VersaTrial, echoed these sentiments, commenting that “Joining forces with Florence Healthcare is a monumental leap forward for VersaTrial and for research sites globally.
“Florence Healthcare’s proven track record digitizing clinical trial sites globally at scale will undoubtedly enhance the impact of our solutions,” he said.
The deal follows a few months after Florence launched what it calls a “Site Enablement League,” designed to together trial leaders from research sites, sponsors, patients, CROs and to collaborate on the development of best-practices that accelerate study start-up.
According to recent research sponsored by Florence clinical trial sites that use site enablement platforms can accelerate clinical trials by as many as six weeks and reduce costs by more than $1 million per study.
DepositPhotos/buchachon_photo